Literature DB >> 16603398

Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO.

Chee-Kwee Ea1, Li Deng, Zong-Ping Xia, Gabriel Pineda, Zhijian J Chen.   

Abstract

The receptor interacting protein kinase 1 (RIP1) is essential for the activation of nuclear factor kappaB (NF-kappaB) by tumor necrosis factor alpha (TNFalpha). Here, we present evidence that TNFalpha induces the polyubiquitination of RIP1 at Lys-377 and that this polyubiquitination is required for the activation of IkappaB kinase (IKK) and NF-kappaB. A point mutation of RIP1 at Lys-377 (K377R) abolishes its polyubiquitination as well as its ability to restore IKK activation in a RIP1-deficient cell line. The K377R mutation of RIP1 also prevents the recruitment of TAK1 and IKK complexes to TNF receptor. Interestingly, polyubiquitinated RIP1 recruits IKK through the binding between the polyubiquitin chains and NEMO, a regulatory subunit of the IKK complex. Mutations of NEMO that disrupt its polyubiquitin binding also abolish IKK activation. These results reveal the biochemical mechanism underlying the essential signaling function of NEMO and provide direct evidence that signal-induced site-specific ubiquitination of RIP1 is required for IKK activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16603398     DOI: 10.1016/j.molcel.2006.03.026

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  449 in total

1.  Epstein-Barr latent membrane protein 1 transformation site 2 activates NF-kappaB in the absence of NF-kappaB essential modifier residues 133-224 or 373-419.

Authors:  Daniela Boehm; Benjamin E Gewurz; Elliott Kieff; Ellen Cahir-McFarland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

2.  Lys48-linked TAK1 polyubiquitination at lysine-72 downregulates TNFα-induced NF-κB activation via mediating TAK1 degradation.

Authors:  Yihui Fan; Yi Shi; Shangfeng Liu; Renfang Mao; Lei An; Yanling Zhao; Hong Zhang; Fuchun Zhang; Guotong Xu; Jun Qin; Jianhua Yang
Journal:  Cell Signal       Date:  2012-03-03       Impact factor: 4.315

Review 3.  Programmed necrosis: backup to and competitor with apoptosis in the immune system.

Authors:  Jiahuai Han; Chuan-Qi Zhong; Duan-Wu Zhang
Journal:  Nat Immunol       Date:  2011-11-16       Impact factor: 25.606

Review 4.  Roles for the ubiquitin-proteasome pathway in protein quality control and signaling in the retina: implications in the pathogenesis of age-related macular degeneration.

Authors:  Fu Shang; Allen Taylor
Journal:  Mol Aspects Med       Date:  2012-04-10

Review 5.  Cellular and molecular biology of optineurin.

Authors:  Hongyu Ying; Beatrice Y J T Yue
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 6.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 7.  Deciphering the complexity of Toll-like receptor signaling.

Authors:  Renato Ostuni; Ivan Zanoni; Francesca Granucci
Journal:  Cell Mol Life Sci       Date:  2010-07-31       Impact factor: 9.261

8.  A bimolecular affinity purification method under denaturing conditions for rapid isolation of a ubiquitinated protein for mass spectrometry analysis.

Authors:  Gabriel N Maine; Haiying Li; Iram W Zaidi; Venkatesha Basrur; Kojo S J Elenitoba-Johnson; Ezra Burstein
Journal:  Nat Protoc       Date:  2010-07-22       Impact factor: 13.491

9.  Molluscum Contagiosum Virus MC159 Abrogates cIAP1-NEMO Interactions and Inhibits NEMO Polyubiquitination.

Authors:  Sunetra Biswas; Joanna L Shisler
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

10.  Inhibition of NF-kappaB activation with designed ankyrin-repeat proteins targeting the ubiquitin-binding/oligomerization domain of NEMO.

Authors:  Emanuel Wyler; Monika Kaminska; Yves-Marie Coïc; Françoise Baleux; Michel Véron; Fabrice Agou
Journal:  Protein Sci       Date:  2007-09       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.